ArticleCancer cell2020
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 488 papers.
0numbers the graph read from it
0cells of the map it votes in
488citing papers in PubMed
36.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
488 citing papers in PubMed, 750 citations in OpenAlex.
- The role, regulatory mechanisms, and therapeutic implications of FTO in gastrointestinal cancer.Genes & diseases · 2026Review
- Article
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- Review
- Targeting the SETD2-FTO-KIT pathway as a pharmacological strategy for TKI-refractory GIST.Acta pharmaceutica Sinica. B · 2026Article
- Development of m6A-related prognostic models for survival in lung squamous cell carcinoma with different PD-L1 expression levels.Translational cancer research · 2026Article
- AL398, A Novel NSUN6 Inhibitor, Attenuates Epithelial-Mesenchymal Transition and Metastasis in Endometrial Cancer by Abrogating m5C-Dependent Stabilization of Snail mRNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.Leukemia · 2026Article
- Functional Role of ALKBH5 in Kidney Injury: Insights Into Mechanisms and Therapeutic Potential.Journal of cellular biochemistry · 2026Review
- Review
- FTO in Bone Diseases: Functions, Mechanisms and Therapeutic Potential.Biomolecules · 2026Review
- Can Disruption of Circadian Rhythms Be Linked to Radiation-Induced Acute Myeloid Leukaemia?Cancers · 2026Review
- Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications.Journal of hematology & oncology · 2026Review
- A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC.Science advances · 2026Article
- Review
- mPharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- The relevance of mJournal of cancer research and clinical oncology · 2026Review
- The Role of NMedComm · 2026Review
428 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
39 authors at 11 institutions in 2 countries.
Rui SuDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Lei DongDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Yangchan LiDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
Min GaoDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; School of Pharmaceutical Science and Technology, Tianjin Key Laboratory for Modern Drug Delivery and High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineer (Tianjin), Tianjin University, Tianjin 300072, China.
Li HanDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; School of Pharmacy, China Medical University, Shenyang, Liaoning 110001, China.
Mark WunderlichDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Xiaolan DengDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Hongzhi LiDepartment of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Yue HuangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Lei GaoDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Pathology and Genomic Medicine, Houston Methodist, Houston, TX 77030, USA.
Chenying LiDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 31003, China.
Zhicong ZhaoDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Sean RobinsonDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Brandon TanDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Ying QingDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Xi QinDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Emily PrinceDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Jun XieDepartment of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Hanjun QinThe Integrative Genomics Core, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA.
Wei LiDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Chao ShenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Jie SunDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Prakash KulkarniDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA.
Hengyou WengDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Huilin HuangDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Zhenhua ChenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
Bin ZhangDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA.
Xiwei WuThe Integrative Genomics Core, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA.
Mark J OlsenDepartment of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern University, Glendale, AZ 85308, USA.
Markus MüschenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA.
Guido MarcucciDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA.
Ravi SalgiaDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA.
Ling LiDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA.
Amir T FathiMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
Zejuan LiDepartment of Pathology and Genomic Medicine, Houston Methodist, Houston, TX 77030, USA.
James C MulloyDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Minjie WeiSchool of Pharmacy, China Medical University, Shenyang, Liaoning 110001, China.
David HorneDepartment of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Jianjun ChenDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA. Electronic address: jianchen@coh.org.
City of Hope · USBeckman Research InstituteChina Medical University · CNCincinnati Children's Hospital Medical Center · USHarvard University · USHouston Methodist · USMethodist Hospital · USMidwestern University · USShanghai Institute of Materia Medica · CNShanghai Jiao Tong University · CNSun Yat-sen University · CN
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MMetabolic gatekeepers in B-cell malignanciesR35CA197628 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2016 to 2026
$11.7MTargeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7MECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTERU10CA180827 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI LEVINE, ROSS L, MELNICK, ARI M. · 2014 to 2018
$3.0MTargeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8MPRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIAR01CA137060 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2009 to 2016
$2.7MThe role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3MTargeting TET1 signaling to treat acute myeloid leukemiaR01CA211614 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.3MThe function and underlying mechanism of TET1 in myelodysplastic syndromesR01DK124116 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2023
$2.2MThe role and mechanism of FTO in leukemogenesis and drug responseR01CA214965 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.1MDNA Damage Response and Oncogenic SignalingT32CA186895 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BINGHUI SHEN, Jeremy Michael Stark · 2016 to 2026
$2.1MCD25-mediated feedback control of BCR-signaling and its oncogenic mimicsR01CA213138 · NCI · YALE UNIVERSITY · PI MÜSCHEN, MARKUS · 2017 to 2022
$1.9MHoward Hughes Medical InstituteNCI NIH HHS P30 CA033572NCI NIH HHS R01 CA137060NCI NIH HHS R01 CA157644NCI NIH HHS R01 CA169458NCI NIH HHS R01 CA172558NCI NIH HHS R01 CA211614NCI NIH HHS R01 CA213138NCI NIH HHS R01 CA214965NCI NIH HHS R01 CA236399NCI NIH HHS R01 CA243386NCI NIH HHS R35 CA197628NCI NIH HHS R50 CA211404NCI NIH HHS T32 CA186895NCI NIH HHS U10 CA180827NIDDK NIH HHS R01 DK124116
Abstract
Fat mass and obesity-associated protein (FTO), an RNA N
Indexed as
Alpha-Ketoglutarate-Dependent Dioxygenase FTOAnthracenesBiphenyl CompoundsCell Line, TumorCell Self RenewalCell SurvivalEnzyme InhibitorsGene Expression Regulation, NeoplasticHumansImmune EvasionLeukemiaMembrane GlycoproteinsMolecular StructureProtein BindingProtein DomainsQuinaldinesAlpha-Ketoglutarate-Dependent Dioxygenase FTOAnthracenesBiphenyl CompoundsbisantrenebrequinarEnzyme InhibitorsFTO protein, humanLILRB4 protein, humanMembrane GlycoproteinsQuinaldinesReceptors, ImmunologicFTOimmune checkpoint genesimmune evasioninhibitorsleukemiaLILRB4LSC/LIC self-renewalN(6)-methyladenosine (m(6)A) modificationsolid tumorstherapeutics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.